Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Hive Digital expands BUZZ HPC with new cluster in Quebec, acquires Toronto facility to fuel growth (Proactive Investors) +++ HIVE DIGITAL Aktie -3,44%

ACURX Aktie

 >ACURX Aktienkurs 
0.488 EUR    -3.6%    (Tradegate)
Ask: 0.538 EUR / 9300 Stück
Bid: 0.512 EUR / 9800 Stück
Tagesumsatz: 1800 Stück
Realtime Kurs von 8 bis 22 Uhr!
ACURX Aktie über LYNX handeln
>ACURX Performance
1 Woche: +94,7%
1 Monat: +47,4%
3 Monate: +32,5%
6 Monate: -33,2%
1 Jahr: -76,3%
laufendes Jahr: -39,0%
>ACURX Aktie
Name:  ACURX PHARMACEUT. DL-,001
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US00510M1045 / A3CSCG
Symbol/ Ticker:  3ZO (Frankfurt) / ACXP (NASDAQ)
Kürzel:  FRA:3ZO, ETR:3ZO, 3ZO:GR, NASDAQ:ACXP
Index:  -
Webseite:  https://www.acurxpharma.c..
Marktkapitalisierung:  6.17 Mio. EUR
Umsatz:  -
EBITDA:  -
Gewinn je Aktie:  -0.528 EUR
Schulden:  -
Liquide Mittel:  4.02 Mio. EUR
Umsatz-/ Gewinnwachstum:  - / -
KGV/ KGV lG:  - / -
KUV/ KBV/ PEG:  - / 6.65 / -
Gewinnm./ Eigenkapitalr.:  - / -285.79%
Dividende je Aktie:  -
Dividendenrendite/ -schätzung:  - / -
Insiderhandel:  -
Suchwörter:  ACURX
Letzte Datenerhebung:  24.06.25
>ACURX Eigentümer
Aktien: 23.48 Mio. St.
f.h. Aktien: 18.86 Mio. St.
Insider Eigner: 10.95%
Instit. Eigner: 17.99%
>ACURX Peer Group

 
18.06.25 - 03:51
 Acurx Pharmaceuticals, Inc. Announces Exercise of Warrants for $2.67 Million Gross Proceeds (PR Newswire)
 
STATEN ISLAND, N.Y., June 17, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced that it has entered into a......
17.06.25 - 13:03
 Acurx Announces Publication in Lancet Microbe of Phase 2b Clinical Trial Data for Ibezapolstat in CDI (PR Newswire)
 
As previously reported, 15 out of 16 (94%) patients in Phase 2b in the Per Protocol Population experienced Clinical Cure (CC) and all 15 of 15 (100%) remained free of C. difficile infection (CDI) recurrence through one month after EOT In contrast, 2 of 14 (14%) patients treated with the......
09.06.25 - 13:33
 Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Federation of American Societies for Experimental Biology Scientific Conference (PR Newswire)
 
Results are from Acurx's ongoing scientific collaboration with Leiden University Medical Center (LUMC) partially under a grant from Health Holland to further study the mechanism of action of DNA pol IIIC inhibitors LUMC highlighted Acurx's new class of promising antimicrobials,......
21.05.25 - 22:42
 Acurx files to sell 10.9M shares of common stock for holders (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
13.05.25 - 20:06
 Acurx signals progress in Phase 3 ibezapolstat program with $12M credit line following regulatory alignment (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
13.05.25 - 14:12
 Acurx Pharmaceuticals GAAP EPS of -$0.11 (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
13.05.25 - 13:03
 Acurx Pharmaceuticals, Inc. Reports First Quarter Results and Provides Business Update (PR Newswire)
 
STATEN ISLAND, N.Y., May 13, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and......
30.04.25 - 13:30
 Acurx Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 13, 2025 Conference Call and Provide Business Update (PR Newswire)
 
STATEN ISLAND, N.Y., April 30, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will......
28.04.25 - 13:33
 Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase (PR Newswire)
 
STATEN ISLAND, N.Y., April 28, 2025 /PRNewswire/ -- Acurx Pharmaceuticals (Nasdaq: ACXP) (Acurx or the Company), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections today announced that David P. Luci,......
17.04.25 - 13:31
 Indian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors (PR Newswire)
 
STATEN ISLAND, N.Y., April 17, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, today announced that a new......
16.04.25 - 18:54
 New to The Street Renews Acurx Pharmaceuticals for Exclusive 6-Month Media Series Including Nationwide TV, Earned Media, and Expanded Digital Reach (Accesswire)
 
NEW YORK CITY, NEW YORK / ACCESS Newswire / April 16, 2025 / New to The Street, a premier business television and media platform, is proud to announce the renewal of its media partnership with Acur......
08.04.25 - 17:30
 Acurx Pharmaceuticals (ACXP) May Find a Bottom Soon, Here′s Why You Should Buy the Stock Now (Zacks)
 
After losing some value lately, a hammer chart pattern has been formed for Acurx Pharmaceuticals (ACXP), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term....
21.03.25 - 18:45
 Acurx Pharmaceuticals (ACXP) Upgraded to Buy: Here′s What You Should Know (Zacks)
 
Acurx Pharmaceuticals (ACXP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy)....
18.03.25 - 12:12
 Acurx Pharmaceuticals GAAP EPS of -$0.87 (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
18.03.25 - 12:03
 Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update (PR Newswire)
 
STATEN ISLAND, N.Y., March 18, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and......
14.03.25 - 18:18
 New to The Street & Sight & Sound′s Visionaries Series Premieres Tomorrow on Bloomberg at 6:30 PM EST, Featuring Acurx Pharmaceuticals NASDAQ:ACXP (Accesswire)
 
NEW YORK CITY, NY / ACCESS Newswire / March 14, 2025 / The highly anticipated Visionaries Series from New to The Street and Sight & Sound premieres tomorrow on Bloomberg at 6:30 PM EST as sponsored......
10.03.25 - 21:30
 Acurx Pharmaceuticals, Inc. Announces Closing of $1.1 Million Registered Direct Offering (PR Newswire)
 
STATEN ISLAND, N.Y., March 10, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced the closing of its......
07.03.25 - 17:48
 Why Acurx Pharmaceuticals (ACXP) Shares Are Down 30% (Benzinga)
 
Acurx Pharmaceuticals shares are trading lower by 30% during Friday's session. The company announced a $1.1 million registered direct offering. read more...
07.03.25 - 14:18
 Acurx Pharmaceuticals stock sinks on $1.1M direct offering (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Was man zu lang bedenkt, das wird bedenklich. - Sprichwort
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!